PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-U.S. directs millions of COVID-19 shots to Latin America, Africa, Asia

Mon, 21st Jun 2021 17:33

(Adds comments from White House spokesperson)

By Jeff Mason

June 21 (Reuters) - The White House laid out a plan on
Monday to share 55 million U.S. COVID-19 vaccine doses globally,
with roughly 75% of the doses allocated to Latin America and the
Caribbean, Asia and Africa through the COVAX international
vaccine-sharing program.

The plan fulfills President Joe Biden's commitment to share
80 million U.S.-made vaccines with countries around the world.
The president sketched out his priorities for the first 25
million doses from that pledge earlier this month.

The United States has come under pressure to share more of
its vaccine supply with countries that are still struggling with
the deadly virus and its variants. With more and more Americans
getting the shots, the White House increasingly has turned its
attention to getting vaccine out internationally. (Graphic on
global vaccinations) https://tmsnrt.rs/3tUM8ta

Of the 55 million remaining doses, some 41 million will be
shared through COVAX, the White House said, with approximately
14 million going to Latin America and the Caribbean, some 16
million to Asia, and roughly 10 million to Africa.

The other 25%, or roughly 14 million doses, will be shared
with "regional priorities," including Colombia, Argentina, Iraq,
Ukraine, the West Bank and Gaza.

White House spokeswoman Jen Psaki said the United States had
faced logistical issues getting vaccine to other nations.

"We have plenty of doses to share with the world, but this
is a Herculean logistical challenge," she told reporters, noting
safety and regulatory information had to be shared, proper
storage temperatures for the vaccines had to be ensured, and
language barriers at times had to be overcome.

"We have announced today where these doses are going. We
will continue to announce as they land on the ground and as they
are being shipped, and we're looking forward to doing that as
quickly as possible," she said.

The 55 million doses will be taken from the U.S. supply of
Pfizer Inc, Moderna Inc, and Johnson & Johnson
shots, though if AstraZeneca's vaccine gets a
green light from the Food and Drug Administration, it would
likely be added to the mix as well.

The White House said it wanted the doses to be prioritized
for health care workers and those who are most at risk.

International partners are eager to get U.S. help. Biden has
announced the United States will buy 500 million doses of
Pfizer's vaccine and donate them to the world's poorest
countries.

The White House's breakdown of its allocation of the 55
million vaccine doses is below.

THROUGH COVAX:

* Latin America and the Caribbean (approximately 14 million
shots): Brazil, Argentina, Colombia, Peru, Ecuador, Paraguay,
Bolivia, Uruguay, Guatemala, El Salvador, Honduras, Haiti, and
other Caribbean Community (CARICOM) countries, Dominican
Republic, Panama, and Costa Rica

* Asia (approximately 16 million shots): India, Nepal,
Bangladesh, Pakistan, Sri Lanka, Afghanistan, Maldives, Bhutan,
Philippines, Vietnam, Indonesia, Thailand, Malaysia, Laos, Papua
New Guinea, Taiwan, Cambodia, and the Pacific Islands.

* Africa (approximately 10 million shots): Recipient
countries will be selected in coordination with the African
Union.

THROUGH DIRECT SHARING: Colombia, Argentina, Haiti, other
CARICOM countries, Dominican Republic, Costa Rica, Panama,
Afghanistan, Bangladesh, Pakistan, Philippines, Vietnam,
Indonesia, South Africa, Nigeria, Kenya, Ghana, Cabo Verde,
Egypt, Jordan, Iraq, Yemen, Tunisia, Oman, West Bank and Gaza,
Ukraine, Kosovo, Georgia, Moldova, and Bosnia.

(Reporting by Jeff Mason
Additional reporting by Trevor Hunnicutt and Nandita Bose
Editing by Chizu Nomiyama and Lisa Shumaker)

More News
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.